<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00234494</url>
  </required_header>
  <id_info>
    <org_study_id>HOG GU04-75</org_study_id>
    <nct_id>NCT00234494</nct_id>
  </id_info>
  <brief_title>Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer</brief_title>
  <official_title>A Phase II Trial of Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer: Hoosier Oncology Group GU04-75</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christopher Sweeney, MBBS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Walther Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoosier Cancer Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoosier Cancer Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cisplatin is a very important agent for the treatment of TCC as it has a single agent
      response rate of approximately 15%. However, it has been most important as a part of
      combination chemotherapy, MVAC initially and now in combination with gemcitabine. Single
      agent gemcitabine has demonstrated an overall response rate (ORR) of approximately 25%,
      including some complete responses (CR), with minimal toxicity in patients with advanced
      bladder cancer. Bevacizumab, a murine anti-human VEGF monoclonal antibody, has been advanced
      for use in combination with cytotoxic chemotherapy to delay time to disease progression in
      patients with metastatic solid tumors.

      This trial is designed to further assess the efficacy, safety and tolerability of this
      regimen in this patient population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: This is a multi-center study.

        -  Cisplatin 70 mg/m2 Day 1

        -  Gemcitabine 1250 mg/m2 Day 1 and 8

        -  Bevacizumab 15 mg/kg Day 1

      Review toxicity every cycle (every 3 weeks) Review for radiographic response every 2 cycles
      (every six weeks)

      Progressive disease = off protocol therapy

      Patients will be treated for up to a maximum of 8 cycles of cisplatin and gemcitabine (24
      weeks of therapy). If a patient has not progressed by the end of 24 weeks (completion of
      cisplatin and gemcitabine), then patient will be treated with bevacizumab at 15 mg/kg every
      three weeks for a maximum of 12 months of bevacizumab therapy (since study entry).

      If at any time patient has undue toxicity or progressive disease, patient will be removed
      from the study and followed until progression and for survival.

      If the patient has Grade 3 or 4 neurotoxicity and/or the creatinine rises above 2.0, then the
      cisplatin will be discontinued and the patient continued on study and treated with
      gemcitabine and bevacizumab at the same dose and schedule.

      ECOG Performance Status 0 or 1

      Hematopoietic:

        -  White blood cell count &gt; 3000/mm3

        -  Absolute neutrophil count (ANC) &gt; 1500 mm/3

        -  Platelet count &gt; 100,000/mm3

        -  Hemoglobin &gt; 8 g/dL (may be transfused or receive erythropoietin support to maintain or
           exceed this level).

        -  INR &lt; 1.5

        -  No full dose/therapeutic anticoagulation with either low molecular weight heparin or
           unfractionated heparin or coumadin

      Hepatic:

        -  Total bilirubin of &lt;1.5 mg/dL

        -  ALT &lt;5 times upper limit of normal for subjects with documented liver metastases; &lt;2.5
           times the upper limit of normal for subjects without evidence of liver metastases.

      Renal:

        -  Serum creatinine of &lt; 1.5 mg/dL.

        -  Urine protein:creatinine ratio &lt; 1.0 at screening

      Cardiovascular:

        -  No history of myocardial infarction or stroke within the last 6 months

        -  No uncontrolled hypertension (blood pressure of &gt;160 systolic and/or 110 diastolic mmHg
           on medication)

        -  No unstable angina, New York Heart Association (NYHA) Grade II or greater congestive
           heart failure

        -  No unstable symptomatic arrhythmia requiring medication (subjects with chronic atrial
           arrhythmia, i.e., atrial fibrillation or paroxysmal supraventricular tachycardia are
           eligible), or clinically significant peripheral vascular disease.

      Pulmonary:

        -  Not specified
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>36 months</time_frame>
    <description>- To determine the progression free survival of patients with metastatic transitional cell cancer treated with cisplatin, gemcitabine and bevacizumab.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Time</measure>
    <time_frame>36 months</time_frame>
    <description>To estimate overall survival time in months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate Response Rates</measure>
    <time_frame>36 months</time_frame>
    <description>To estimate rate of partial response (PR), complete response (CR) and overall response (PR plus CR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response for Responding Patients</measure>
    <time_frame>36 months</time_frame>
    <description>To estimate duration of response for responding patients.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Single Group Assignment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin + Gemcitabine + Bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 70 mg/m2, day 1</description>
    <arm_group_label>Single Group Assignment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 1250 mg/m2, day 1 and 8</description>
    <arm_group_label>Single Group Assignment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab 15mg/kg, day 1</description>
    <arm_group_label>Single Group Assignment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously untreated or relapsed locally advanced or metastatic transitional cell
             carcinoma of the bladder. (Patients with pathology showing ANY component of
             non-transitional cell histology are not eligible).

          -  Relapsed patients may have received prior chemotherapy â‰¥ one year prior to study
             registration as part of a neoadjuvant or adjuvant regimen and must not have had
             intervening therapy from the end of that treatment until study entry.

          -  Measurable disease as per RECIST.

          -  Prior radiation therapy, immunotherapy, cytokine, biologic or vaccine therapy must be
             greater than 28 days prior to being registered for protocol therapy,

        Exclusion Criteria:

          -  No known central nervous system metastasis. (imaging of brain only required if
             clinically indicated)

          -  No prior organ allograft.

          -  No history of other disease, metabolic dysfunction, physical examination finding, or
             clinical laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates the use of an investigational drug or that might affect the
             interpretation of the results of the study or render the subject at high risk from
             treatment complications.

          -  No evidence of bleeding diathesis or coagulopathy.

          -  No history of serious, non-healing wound, ulcer or bone fracture

          -  No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal
             abscess within 6 months prior to being registered for protocol therapy.

          -  No prior history of malignancy in the past 5 years with the exception of basal cell
             and squamous cell carcinoma of the skin. Other cancers with low potential for
             metastasis, such as in situ cancers (e.g., Grade 1, TA TCC (low grade superficial
             bladder cancer), colonic polyp with focus of adenocarcinoma) can also be enrolled
             after approval from the study chair.

          -  No major surgical procedure, open biopsy, or significant traumatic injury less than 28
             days prior to being registered for protocol therapy.

          -  Patients are not eligible if the need for any major surgical procedure is anticipated
             during the course of the study.

          -  Any minor surgical procedures, fine needle aspirations or core biopsies must be
             greater than 7 days prior to being registered for protocol therapy except procedures
             to secure a vascular access device which must be greater than 7 days prior to the
             start of protocol therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Sweeney, M.B.B.S.</last_name>
    <role>Study Chair</role>
    <affiliation>Hoosier Oncology Group, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical &amp; Surgical Specialists, LLC</name>
      <address>
        <city>Galesburg</city>
        <state>Illinois</state>
        <zip>61401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Associates of SW Indiana</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Oncology &amp; Hematology, Inc</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Cancer Center (MCGOP)</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arnett Cancer Care</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Indiana Cancer Research Consortium</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP&amp;S Clinic</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hoosiercancer.org</url>
    <description>Hoosier Cancer Research Network Homepage</description>
  </link>
  <results_reference>
    <citation>Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J, Nattam S, Johnson CS, Perkins SM, Waddell MJ, Sweeney CJ; Hoosier Oncology Group. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol. 2011 Apr 20;29(12):1525-30. doi: 10.1200/JCO.2010.31.6067. Epub 2011 Mar 21.</citation>
    <PMID>21422406</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2005</study_first_submitted>
  <study_first_submitted_qc>October 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2005</study_first_posted>
  <results_first_submitted>January 19, 2016</results_first_submitted>
  <results_first_submitted_qc>February 16, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 14, 2016</results_first_posted>
  <last_update_submitted>February 16, 2016</last_update_submitted>
  <last_update_submitted_qc>February 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hoosier Cancer Research Network</investigator_affiliation>
    <investigator_full_name>Christopher Sweeney, MBBS</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single Group Assignment</title>
          <description>Cisplatin + Gemcitabine + Bevacizumab
Cisplatin: Cisplatin 70 mg/m2, day 1
Gemcitabine: Gemcitabine 1250 mg/m2, day 1 and 8
Bevacizumab: Bevacizumab 15mg/kg, day 1</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Group Assignment</title>
          <description>Cisplatin + Gemcitabine + Bevacizumab
Cisplatin: Cisplatin 70 mg/m2, day 1
Gemcitabine: Gemcitabine 1250 mg/m2, day 1 and 8
Bevacizumab: Bevacizumab 15mg/kg, day 1</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="41" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index, kg/m2</title>
          <units>kg/m2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.7" lower_limit="19.1" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Creatinine, mg/dL</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.1" lower_limit="0.6" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>WBC Count</title>
          <units>K/ul</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7600" lower_limit="4100" upper_limit="22000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin</title>
          <units>g/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.0" lower_limit="9.1" upper_limit="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Platelet count</title>
          <units>platelets per ul</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="291000" lower_limit="139000" upper_limit="770000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of metastatic sites</title>
          <units>number of metastatic sites</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior cystectomy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) Performance Status</title>
          <description>Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) from 0-5 that describes a patient's level of functioning where 0=Fully active, able to carry on all pre-disease performance without restriction and 5=Dead:</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ECOG 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECOG 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Metastatic Site Locations</title>
          <units>number of metastatic sites per location</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Any lymph node</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pelvic/abdominal lymph node</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any visceral metastases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Modified Bajorin risk group</title>
          <description>Modified Bajorin risk groups were defined as follows:PS0 and no visceral metastases(lowrisk); PS1 and no visceral metastases or PS 0 and visceral metastases (intermediate risk); and PS
1 and visceral metastases (high risk)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Good risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor risk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival</title>
        <description>- To determine the progression free survival of patients with metastatic transitional cell cancer treated with cisplatin, gemcitabine and bevacizumab.</description>
        <time_frame>36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Group Assignment</title>
            <description>Cisplatin + Gemcitabine + Bevacizumab
Cisplatin: Cisplatin 70 mg/m2, day 1
Gemcitabine: Gemcitabine 1250 mg/m2, day 1 and 8
Bevacizumab: Bevacizumab 15mg/kg, day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>- To determine the progression free survival of patients with metastatic transitional cell cancer treated with cisplatin, gemcitabine and bevacizumab.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="6.8" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Time</title>
        <description>To estimate overall survival time in months.</description>
        <time_frame>36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Group Assignment</title>
            <description>Cisplatin + Gemcitabine + Bevacizumab
Cisplatin: Cisplatin 70 mg/m2, day 1
Gemcitabine: Gemcitabine 1250 mg/m2, day 1 and 8
Bevacizumab: Bevacizumab 15mg/kg, day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Time</title>
          <description>To estimate overall survival time in months.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1" lower_limit="12.4" upper_limit="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimate Response Rates</title>
        <description>To estimate rate of partial response (PR), complete response (CR) and overall response (PR plus CR).</description>
        <time_frame>36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Group Assignment</title>
            <description>Cisplatin + Gemcitabine + Bevacizumab
Cisplatin: Cisplatin 70 mg/m2, day 1
Gemcitabine: Gemcitabine 1250 mg/m2, day 1 and 8
Bevacizumab: Bevacizumab 15mg/kg, day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Estimate Response Rates</title>
          <description>To estimate rate of partial response (PR), complete response (CR) and overall response (PR plus CR).</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>complete reponse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>partial reponse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>overall response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response for Responding Patients</title>
        <description>To estimate duration of response for responding patients.</description>
        <time_frame>36 months</time_frame>
        <population>Data for this secondary outcome measure was not collected or analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Group Assignment</title>
            <description>Cisplatin + Gemcitabine + Bevacizumab
Cisplatin: Cisplatin 70 mg/m2, day 1
Gemcitabine: Gemcitabine 1250 mg/m2, day 1 and 8
Bevacizumab: Bevacizumab 15mg/kg, day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response for Responding Patients</title>
          <description>To estimate duration of response for responding patients.</description>
          <population>Data for this secondary outcome measure was not collected or analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Single Group Assignment</title>
          <description>Cisplatin + Gemcitabine + Bevacizumab
Cisplatin: Cisplatin 70 mg/m2, day 1
Gemcitabine: Gemcitabine 1250 mg/m2, day 1 and 8
Bevacizumab: Bevacizumab 15mg/kg, day 1</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAEv3</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>HEMOGLOBIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PLATELETS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIAC GENERAL - OTHER (SPECIFY, __)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR AND NODAL ARRHYTHMIA / SINUS BRADYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCLE WEAKNESS, GENERALIZED OR SPECIFIC AREA (NOT DUE TO NEUROPATHY) / EXTRAOCULAR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE, GI / ABDOMEN NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PAIN / ABDOMEN NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FEVER (IN THE ABSENCE OF NEUTROPENIA, WHERE NEUTROPENIA IS DEFINED AS ANC &lt;1.0 X 10E9/L)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PAIN / BACK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>FEBRILE NEUTROPENIA (ANC &lt;1.0 X 10E9/L, FEVER &gt;=38.5 DEGREES C)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>INFECTION WITH GRADE 3 OR 4 NEUTROPHILS (ANC &lt;1.0 X 10E9/L) / URINARY TRACT NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>INFECTION WITH NORMAL ANC OR GRADE 1 OR 2 NEUTROPHILS / CATHETER-RELATED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>INFECTION WITH NORMAL ANC OR GRADE 1 OR 2 NEUTROPHILS / SCROTUM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>INFECTION WITH NORMAL ANC OR GRADE 1 OR 2 NEUTROPHILS / URINARY TRACT NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>PROTEINURIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CONFUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE, CNS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>SEIZURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>OBSTRUCTION, GU / URETER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>PHLEBITIS (INCLUDING SUPERFICIAL THROMBOSIS)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>THROMBOSIS/THROMBUS/EMBOLISM</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>VESSEL INJURY-ARTERY / AORTA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAEv3</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>BLOOD/BONE MARROW - OTHER (SPECIFY, __)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>EDEMA: LIMB</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>HEMOGLOBIN</sub_title>
                <counts group_id="E1" events="43" subjects_affected="20" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>LEUKOCYTES (TOTAL WBC)</sub_title>
                <counts group_id="E1" events="15" subjects_affected="8" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>NEUTROPHILS/GRANULOCYTES (ANC/AGC)</sub_title>
                <counts group_id="E1" events="36" subjects_affected="22" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PLATELETS</sub_title>
                <counts group_id="E1" events="21" subjects_affected="10" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIAC GENERAL - OTHER (SPECIFY, __)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="19" subjects_affected="14" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR SYSTOLIC DYSFUNCTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>AUDITORY/EAR - OTHER (SPECIFY, __)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>HEARING: PATIENTS WITHOUT BASELINE AUDIOGRAM AND NOT ENROLLED IN A MONITORING PROGRAM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PAIN / EXTERNAL EAR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>TINNITUS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HOT FLASHES/FLUSHES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PANCREATIC ENDOCRINE: GLUCOSE INTOLERANCE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>THYROID FUNCTION, LOW (HYPOTHYROIDISM)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>MUSCLE WEAKNESS, GENERALIZED OR SPECIFIC AREA (NOT DUE TO NEUROPATHY) / EXTRAOCULAR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>OCULAR/VISUAL - OTHER (SPECIFY, __)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>OPHTHALMOPLEGIA/DIPLOPIA (DOUBLE VISION)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>VISION-BLURRED VISION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>VISION-PHOTOPHOBIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" events="38" subjects_affected="26" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="32" subjects_affected="25" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>DISTENSION/BLOATING, ABDOMINAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>DRY MOUTH/SALIVARY GLAND (XEROSTOMIA)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>GASTRITIS (INCLUDING BILE REFLUX GASTRITIS)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL - OTHER (SPECIFY, __)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>HEARTBURN/DYSPEPSIA</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE, GU / BLADDER</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>MUCOSITIS/STOMATITIS (FUNCTIONAL/SYMPTOMATIC) / ORAL CAVITY</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="67" subjects_affected="31" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PAIN / ABDOMEN NOS</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PAIN / ANUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PAIN / DENTAL/TEETH/PERIDONTAL</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PAIN / RECTUM</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PAIN / STOMACH</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>TASTE ALTERATION (DYSGEUSIA)</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="40" subjects_affected="15" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CONSTITUTIONAL SYMPTOMS - OTHER (SPECIFY, __)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>FATIGUE (ASTHENIA, LETHARGY, MALAISE)</sub_title>
                <counts group_id="E1" events="64" subjects_affected="35" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>FEVER (IN THE ABSENCE OF NEUTROPENIA, WHERE NEUTROPENIA IS DEFINED AS ANC &lt;1.0 X 10E9/L)</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE/BLEEDING - OTHER (SPECIFY, __)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="20" subjects_affected="14" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PAIN / BACK</sub_title>
                <counts group_id="E1" events="18" subjects_affected="12" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PAIN / HEAD/HEADACHE</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PAIN / PAIN NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PAIN / PELVIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PAIN / PERINEUM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PAIN - OTHER (SPECIFY, __)</sub_title>
                <counts group_id="E1" events="15" subjects_affected="10" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>RIGORS/CHILLS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>SWEATING (DIAPHORESIS)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>WEIGHT LOSS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGIC RHINITIS (INCLUDING SNEEZING, NASAL STUFFINESS, POSTNASAL DRIP)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFECTION WITH GRADE 3 OR 4 NEUTROPHILS (ANC &lt;1.0 X 10E9/L) / DENTAL-TOOTH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>INFECTION WITH GRADE 3 OR 4 NEUTROPHILS (ANC &lt;1.0 X 10E9/L) / URINARY TRACT NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>INFECTION - OTHER (SPECIFY, __)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>INFECTION WITH NORMAL ANC OR GRADE 1 OR 2 NEUTROPHILS / ABDOMEN NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>INFECTION WITH NORMAL ANC OR GRADE 1 OR 2 NEUTROPHILS / BLADDER (URINARY)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>INFECTION WITH NORMAL ANC OR GRADE 1 OR 2 NEUTROPHILS / BRONCHUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>INFECTION WITH NORMAL ANC OR GRADE 1 OR 2 NEUTROPHILS / COLON</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>INFECTION WITH NORMAL ANC OR GRADE 1 OR 2 NEUTROPHILS / CONJUNCTIVA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>INFECTION WITH NORMAL ANC OR GRADE 1 OR 2 NEUTROPHILS / EYE NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>INFECTION WITH NORMAL ANC OR GRADE 1 OR 2 NEUTROPHILS / RECTUM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>INFECTION WITH NORMAL ANC OR GRADE 1 OR 2 NEUTROPHILS / SINUS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>INFECTION WITH NORMAL ANC OR GRADE 1 OR 2 NEUTROPHILS / SKIN (CELLULITIS)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>INFECTION WITH NORMAL ANC OR GRADE 1 OR 2 NEUTROPHILS / URINARY TRACT NOS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>INFECTION WITH UNKNOWN ANC / SINUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>HEMORRHAGE/BLEEDING ASSOCIATED WITH SURGERY, INTRA-OPERATIVE OR POSTOPERATIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALBUMIN, SERUM-LOW (HYPOALBUMINEMIA)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>ALKALINE PHOSPHATASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>ALT, SGPT (SERUM GLUTAMIC PYRUVIC TRANSAMINASE)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>AST, SGOT(SERUM GLUTAMIC OXALOACETIC TRANSAMINASE)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>CALCIUM, SERUM-HIGH (HYPERCALCEMIA)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>CALCIUM, SERUM-LOW (HYPOCALCEMIA)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>CHOLESTEROL, SERUM-HIGH (HYPERCHOLESTREMIA)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>CREATININE</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>GLUCOSE, SERUM-HIGH (HYPERGLYCEMIA)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>MAGNESIUM, SERUM-LOW (HYPOMAGNESEMIA)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY - OTHER (SPECIFY, __)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>POTASSIUM, SERUM-HIGH (HYPERKALEMIA)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>POTASSIUM, SERUM-LOW (HYPOKALEMIA)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PROTEINURIA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>SODIUM, SERUM-LOW (HYPONATREMIA)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRITIS (NON-SEPTIC)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>MUSCLE WEAKNESS, GENERALIZED OR SPECIFIC AREA (NOT DUE TO NEUROPATHY) / EXTREMITY-UPPER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>MUSCLE WEAKNESS, GENERALIZED OR SPECIFIC AREA (NOT DUE TO NEUROPATHY) / WHOLE BODY/GENERALIZED</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL/SOFT TISSUE - OTHER (SPECIFY, __)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PAIN / BONE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PAIN / EXTREMITY-LIMB</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PAIN / JOINT</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PAIN / MUSCLE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CONFUSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>NEUROLOGY - OTHER (SPECIFY, __)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>NEUROPATHY: MOTOR</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>NEUROPATHY: SENSORY</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>MOOD ALTERATION / AGITATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>MOOD ALTERATION / ANXIETY</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>MOOD ALTERATION / DEPRESSION</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>PAIN / BLADDER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PAIN / KIDNEY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PAIN / URETHRA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>RENAL/GENITOURINARY - OTHER (SPECIFY, __)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>URINARY FREQUENCY/URGENCY</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION (INCLUDING NEUROGENIC BLADDER)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>URINE COLOR CHANGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>PAIN / PENIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PAIN / VAGINA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="15" subjects_affected="10" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>DYSPNEA (SHORTNESS OF BREATH)</sub_title>
                <counts group_id="E1" events="20" subjects_affected="12" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>FISTULA, PULMONARY/UPPER RESPIRATORY / LUNG</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE, PULMONARY/UPPER RESPIRATORY / NOSE</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>HICCOUGHS (HICCUPS, SINGULTUS)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>NASAL CAVITY/PARANASAL SINUS REACTIONS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PAIN / CHEST/THORAX NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PAIN / THROAT/PHARYNX/LARYNX</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PNEUMONITIS/PULMONARY INFILTRATES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PULMONARY/UPPER RESPIRATORY - OTHER (SPECIFY, __)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>VOICE CHANGES/DYSARTHRIA (E.G., HOARSENESS, LOSS OR ALTERATION IN VOICE, LARYNGITIS)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATOLOGY/SKIN - OTHER (SPECIFY, __)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>HAIR LOSS/ALOPECIA (SCALP OR BODY)</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>INJECTION SITE REACTION/EXTRAVASATION CHANGES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>PRURITUS/ITCHING</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>RASH/DESQUAMATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>RASH: ACNE/ACNEIFORM</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>WOUND COMPLICATION, NON-INFECTIOUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>MUCOSITIS/STOMATITIS (CLINICAL EXAM) / ORAL CAVITY</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>PHLEBITIS (INCLUDING SUPERFICIAL THROMBOSIS)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>THROMBOSIS/THROMBUS/EMBOLISM</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Principal Investigator</name_or_title>
      <organization>Hoosier Cancer Research Network, Inc.</organization>
      <phone>317-921-2050</phone>
      <email>jsmith@hoosiercancer.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

